DexCom, Inc. $DXCM Position Boosted by C WorldWide Group Holding A S

C WorldWide Group Holding A S lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 484,000 shares of the medical device company’s stock after buying an additional 35,000 shares during the quarter. DexCom accounts for about 0.6% of C WorldWide Group Holding A S’s holdings, making the stock its 24th biggest holding. C WorldWide Group Holding A S’s holdings in DexCom were worth $32,123,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of DXCM. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the last quarter. Empowered Funds LLC lifted its position in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the last quarter. Focus Partners Wealth lifted its position in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Mizuho set a $75.00 target price on shares of DexCom in a report on Friday, May 1st. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Finally, Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.50.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $60.61 on Monday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average price is $65.10 and its two-hundred day moving average price is $66.29. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a market capitalization of $23.39 billion, a P/E ratio of 25.90, a P/E/G ratio of 1.04 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 earnings per share. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.56 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.